GlassScriptPhysician profile
Suresh Sabbenahalli
NPI 1528372505
$9,953.71
in general payments reported to CMS, 2019-2025
24 companies · $1,904 in 2025
The $1,904 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $230 · 2021: $1,111 · 2022: $1,228 · 2023: $3,105 · 2024: $1,816 · 2025: $1,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,091 · Travel and Lodging: $715 · Education: $17.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,091.35 |
| Travel and Lodging | $715.39 |
| Education | $17.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,380.04 | 2023 | Neurostar Tms Therapy System |
| Alkermes, INC. | $1,239.08 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $1,221.16 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Abbvie INC. | $960.77 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $773.96 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $695.95 | 2020-2025 | Caplyta |
| Lundbeck LLC | $680.90 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $673.29 | 2020-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $579.68 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $365.31 | 2020-2025 | Trintellix |
| Indivior INC. | $208.72 | 2023-2024 | Perseris, Sublocade |
| E.R. Squibb & Sons, L.L.C. | $203.62 | 2024-2025 | Cobenfy |
| Janssen Scientific Affairs, LLC | $198.00 | 2019 | |
| Vanda Pharmaceuticals INC. | $169.21 | 2021-2024 | Fanapt, Hetlioz |
| Braeburn INC. | $138.57 | 2024-2025 | Brixadi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $103.41 | 2022-2024 | Auvelity |
| Allergan, INC. | $101.44 | 2019-2020 | |
| Livanova USA, INC. | $86.54 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Ironshore Pharmaceuticals INC. | $84.57 | 2023-2024 | Jornay Pm |
| Corium, LLC | $29.65 | 2023 | Azstarys |
| Avanir Pharmaceuticals, INC. | $16.75 | 2019 | |
| Noven Therapeutics, LLC | $16.15 | 2021 | |
| Collegium Pharmaceutical, INC. | $14.38 | 2025 | Jornay Pm |
| Shire North American Group INC | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Sabbenahalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.